Harnessing CD8+CD28− regulatory T cells as a tool to treat autoimmune disease

Ceeraz, Sabrina, Thompson, Charlotte R., Beatson, Richard and Choy, Ernest H. ORCID: https://orcid.org/0000-0003-4459-8609 2021. Harnessing CD8+CD28− regulatory T cells as a tool to treat autoimmune disease. Cells 10 (11) , 2973. 10.3390/cells10112973

Preview

PDF - Published Version Available under License Creative Commons Attribution. Download (749kB) | Preview

Abstract

T regulatory cell therapy presents a novel therapeutic strategy for patients with autoimmune diseases or who are undergoing transplantation. At present, the CD4+ Treg population has been extensively characterized, as a result of defined phenotypic and functional readouts. In this review article, we discuss the development and biology of CD8+ Tregs and their role in murine and human disease indications. A subset of CD8+ Tregs that lack the surface expression of CD28 (CD8+CD28− Treg) has proved efficacious in preclinical models. CD8+CD28− Tregs are present in healthy individuals, but their impaired functionality in disease renders them less effective in mediating immunosuppression. We primarily focus on harnessing CD8+ Treg cell therapy in the clinic to support current treatment for patients with autoimmune or inflammatory conditions.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine
Additional Information:	This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https:// creativecommons.org/licenses/by/ 4.0/).
Publisher:	MDPI
ISSN:	2073-4409
Date of First Compliant Deposit:	26 January 2022
Date of Acceptance:	28 October 2021
Last Modified:	07 May 2023 08:21
URI:	https://orca.cardiff.ac.uk/id/eprint/146957

Citation Data

Cited 10 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item